Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AGN-190168 in Acne Vulgaris
NCT02218034Phase 1Completed
- Sponsor
- Allergan
- Start
- Aug 2014
- Primary completion
- Mar 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised trial of tazarotene in acne vulgaris (4 arms), sponsored by Allergan. Primary endpoints: Maximum Plasma Level of AGN-190168 at Day 29, Maximum Plasma Level of AGN-190168 Metabolite at Day 29 and 2 more. Started Aug 2014; status: completed.
02
Drugs
tazarotene
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT02218034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02218034.